Clinical Trials
47 trialsLow Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca
City of Hope Medical Center
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
AIMSS-RPS
University of Michigan Rogel Cancer Center
TBCRC042
Baylor Breast Care Center
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Mayo Clinic
NOVEMBER
University of Utah
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
Mayo Clinic
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
TOLERANT
European Institute of Oncology
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Mayo Clinic
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
Northwestern University
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Alliance for Clinical Trials in Oncology
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
National Cancer Institute (NCI)
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Eastern Cooperative Oncology Group
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Northwestern University
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
Mayo Clinic
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Radiation Therapy Oncology Group
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
National Cancer Institute (NCI)
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Dana-Farber Cancer Institute
Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors
Fred Hutchinson Cancer Center
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
Wake Forest University Health Sciences
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Jonsson Comprehensive Cancer Center
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
Case Comprehensive Cancer Center
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
University of Texas Southwestern Medical Center
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
WISE
Dana-Farber Cancer Institute
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Masonic Cancer Center, University of Minnesota
Curcumin-II
University of Rochester
NRR
UNC Lineberger Comprehensive Cancer Center
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Roswell Park Cancer Institute
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
Alliance for Clinical Trials in Oncology
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
Fox Chase Cancer Center
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer
Virginia Commonwealth University
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
Vanderbilt-Ingram Cancer Center
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer
University of California, San Francisco
NACprotocol
Auxilio Mutuo Cancer Center
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
National Cancer Institute (NCI)